Atrial Flutter Clinical Trial
Official title:
A Phase II/III Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi-Centred Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Flutter
This study will attempt to demonstrate the effectiveness of RSD1235 in the conversion of atrial flutter (AFL) to sinus rhythm.
There are approximately 2 million reported prevalent cases of atrial fibrillation and atrial
flutter (AFL) in the United States (Heart Disease & Stroke Statistics - 2003 Update, AHA).
These arrhythmias may be occasional or sustained. AF/AFL is usually associated with age, and
general physical condition, rather than with a specific cardiac event, as is often the case
with ventricular arrhythmia. While not directly fatal, these arrhythmias cause discomfort
and can lead to stroke or congestive heart failure.
This Phase II/III trial is Cardiome's first study with RSD1235 for the treatment of atrial
flutter. The study seeks to demonstrate RSD1235's abilities to convert AFL to sinus rhythm.
The patient population will have atrial flutter of duration greater than 3 hours and less
than or equal to 45 days.
This is a double-blind, placebo-controlled, randomized study in patients with AFL;
stratification will be based on duration of AFL. Treatment will be considered successful if
there is a treatment-induced conversion of atrial arrhythmia to sinus rhythm for a minimum
of 1-minute by Hour 1.5 (Time 0 = start of first infusion). All patients will be evaluated
for safety.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Terminated |
NCT02317029 -
Comparison of Oxygen Interventions and Defibrillator Efficiency
|
N/A | |
Recruiting |
NCT01563848 -
Cryoablation in Patients With Atrial Flutter
|
Phase 2 | |
Completed |
NCT01229254 -
Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter
|
Phase 2 | |
Completed |
NCT02065388 -
Pharmacogenetic Dosing of Warfarin
|
Phase 3 | |
Completed |
NCT00839657 -
Clarification of Optimal Anticoagulation Through Genetics
|
Phase 3 | |
Completed |
NCT00232232 -
Use of Fish Oils to Prevent Atrial Mechanical Stunning and Atrial Remodeling Due to Atrial Arrhythmia
|
Phase 4 | |
Completed |
NCT04884100 -
enHEART - Exploring Full Content of Optical Signals to Enhance Cardiac Arrhythmia Screening
|
N/A | |
Completed |
NCT05468281 -
RAFF5 Proposal: Improve the Quality and Safety of Patients Seen in the Emergency Department for Acute Atrial Fibrillation and Flutter
|
||
Completed |
NCT03627143 -
Decreasing Hospital Admissions From the ED for AAFF
|
N/A | |
Completed |
NCT02917538 -
A Randomized Trial of Contact Force in Atrial Flutter Ablation
|
N/A | |
Enrolling by invitation |
NCT05903313 -
A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software
|
||
Recruiting |
NCT05755074 -
Ablation of Typical Right Atrial Flutter
|
N/A | |
Recruiting |
NCT05883631 -
RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.
|
N/A | |
Recruiting |
NCT03272620 -
Atrial Fibrillation at the Viennese University Emergency Department
|
N/A | |
Completed |
NCT02810938 -
MIFI Flutter Registry - Ablation of Atrial Flutter With IntellaTip Sensor Technology
|
||
Recruiting |
NCT02591875 -
Atrial Flutter Ablation in a Real World Population
|
N/A | |
Completed |
NCT01914497 -
Dipole Density Mapping of Typical Atrial Flutter
|
N/A | |
Completed |
NCT02268799 -
High Sensitivity Troponin T Levels Following DC Cardioversion for Atrial Fibrillation / Atrial Flutter
|
N/A | |
Active, not recruiting |
NCT01976507 -
Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism
|
Phase 4 |